Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial.

Sonia S Anand,John W Eikelboom,Leanne Dyal,Jackie Bosch,Christoph Neumann,Petr Widimsky,Alvaro A Avezum,Jeffrey Probstfield, Nancy Cook Bruns,Keith A A Fox,Deepak L Bhatt,Stuart J Connolly,Salim Yusuf

Journal of the American College of Cardiology（2019）

引用 111|浏览32

暂无评分

摘要

In patients with vascular disease, further risk stratification can identify higher-risk patients (≥2 vascular beds affected, HF, renal insufficiency, or diabetes). The net clinical benefit remains favorable for most patients treated with rivaroxaban and aspirin compared with aspirin.

查看译文

关键词

net-clinical benefit,risk stratification,rivaroxaban,vascular disease

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要